PD-1单抗Opdivo联合TKI抑制剂Cabometyx治疗肾癌,获得FDA优先评审

2020-10-21 MedSci原创 MedSci原创

与辉瑞的舒尼替尼(Sunitinib)相比,Opdivo和Cabometyx组合将死亡风险降低了40%。

最新的数据显示,百时美施贵宝(Bristol Myers Squibb)和Exelixis的Opdivo与酪氨酸激酶抑制剂(TKI)Cabometyx组合可以延长肾癌患者的生存期。

Kidney

根据一个月前在欧洲医学肿瘤学会(ESMO)汇报的CheckMate 9ER数据显示,在进行了中位数18个月的随访之后,与辉瑞的舒尼替尼(Sunitinib,sutent)相比,Opdivo和Cabometyx组合将死亡风险降低了40%。

默克和辉瑞的Keytruda和Inlyta同样是使用PD-1抑制剂与TKI的组合疗法,Keynote-426试验中进行了17个月的随访,结果显示与Sutent相比,该联合疗法将死亡风险降低了41%。

并且反应的持续时间也非常相似,Opdivo-Cabometyx的响应时间为20.2个月,而Keytruda-Inlyta的响应时间为20.9个月。

SVB Leerink分析师Daina Graybosch表示,鉴于Keytruda在检查点抑制剂领域的牢固地位,可能会使默克公司占据上风。但是就TKI竞争而言,Exelixis的Cabometyx被批准用作未经治疗肾癌患者的单药治疗药物,似乎比辉瑞的Inlyta更有优势,后者仅获批用于二线治疗。

原始出处:

https://www.fiercepharma.com/marketing/bristol-myers-exelixis-get-fda-fast-lane-for-opdivo-cabometyx-combo-kidney-cancer

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2081218, encodeId=d9112081218db, content=<a href='/topic/show?id=7f1b25e40ce' target=_blank style='color:#2F92EE;'>#优先评审#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25740, encryptionId=7f1b25e40ce, topicName=优先评审)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Sun May 02 04:12:45 CST 2021, time=2021-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896765, encodeId=28991896e657f, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Tue Mar 02 20:12:45 CST 2021, time=2021-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852518, encodeId=92dd1852518b3, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Aug 09 04:12:45 CST 2021, time=2021-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1303104, encodeId=02f8130310432, content=<a href='/topic/show?id=4264134043c' target=_blank style='color:#2F92EE;'>#Opdivo#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13404, encryptionId=4264134043c, topicName=Opdivo)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Fri Oct 23 06:12:45 CST 2020, time=2020-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364905, encodeId=23bb136490543, content=<a href='/topic/show?id=da511390508' target=_blank style='color:#2F92EE;'>#PD-1单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13905, encryptionId=da511390508, topicName=PD-1单抗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8fc0211, createdName=doctor-chen9582, createdTime=Fri Oct 23 06:12:45 CST 2020, time=2020-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1384225, encodeId=4556138422545, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17503, encryptionId=14bb1e503a0, topicName=TKI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b73f484, createdName=lsj628, createdTime=Fri Oct 23 06:12:45 CST 2020, time=2020-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1598075, encodeId=04df15980e570, content=<a href='/topic/show?id=6c6f1e62c5' target=_blank style='color:#2F92EE;'>#ABO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1762, encryptionId=6c6f1e62c5, topicName=ABO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b6c918580135, createdName=闆锋旦, createdTime=Fri Oct 23 06:12:45 CST 2020, time=2020-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621286, encodeId=2d4916212863e, content=<a href='/topic/show?id=5f1f139091f' target=_blank style='color:#2F92EE;'>#PD-1单抗Opdivo#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13909, encryptionId=5f1f139091f, topicName=PD-1单抗Opdivo)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bc4a20243913, createdName=ymljack, createdTime=Fri Oct 23 06:12:45 CST 2020, time=2020-10-23, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2081218, encodeId=d9112081218db, content=<a href='/topic/show?id=7f1b25e40ce' target=_blank style='color:#2F92EE;'>#优先评审#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25740, encryptionId=7f1b25e40ce, topicName=优先评审)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Sun May 02 04:12:45 CST 2021, time=2021-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896765, encodeId=28991896e657f, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Tue Mar 02 20:12:45 CST 2021, time=2021-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852518, encodeId=92dd1852518b3, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Aug 09 04:12:45 CST 2021, time=2021-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1303104, encodeId=02f8130310432, content=<a href='/topic/show?id=4264134043c' target=_blank style='color:#2F92EE;'>#Opdivo#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13404, encryptionId=4264134043c, topicName=Opdivo)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Fri Oct 23 06:12:45 CST 2020, time=2020-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364905, encodeId=23bb136490543, content=<a href='/topic/show?id=da511390508' target=_blank style='color:#2F92EE;'>#PD-1单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13905, encryptionId=da511390508, topicName=PD-1单抗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8fc0211, createdName=doctor-chen9582, createdTime=Fri Oct 23 06:12:45 CST 2020, time=2020-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1384225, encodeId=4556138422545, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17503, encryptionId=14bb1e503a0, topicName=TKI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b73f484, createdName=lsj628, createdTime=Fri Oct 23 06:12:45 CST 2020, time=2020-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1598075, encodeId=04df15980e570, content=<a href='/topic/show?id=6c6f1e62c5' target=_blank style='color:#2F92EE;'>#ABO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1762, encryptionId=6c6f1e62c5, topicName=ABO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b6c918580135, createdName=闆锋旦, createdTime=Fri Oct 23 06:12:45 CST 2020, time=2020-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621286, encodeId=2d4916212863e, content=<a href='/topic/show?id=5f1f139091f' target=_blank style='color:#2F92EE;'>#PD-1单抗Opdivo#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13909, encryptionId=5f1f139091f, topicName=PD-1单抗Opdivo)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bc4a20243913, createdName=ymljack, createdTime=Fri Oct 23 06:12:45 CST 2020, time=2020-10-23, status=1, ipAttribution=)]
    2021-03-02 柳叶一刀
  3. [GetPortalCommentsPageByObjectIdResponse(id=2081218, encodeId=d9112081218db, content=<a href='/topic/show?id=7f1b25e40ce' target=_blank style='color:#2F92EE;'>#优先评审#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25740, encryptionId=7f1b25e40ce, topicName=优先评审)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Sun May 02 04:12:45 CST 2021, time=2021-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896765, encodeId=28991896e657f, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Tue Mar 02 20:12:45 CST 2021, time=2021-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852518, encodeId=92dd1852518b3, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Aug 09 04:12:45 CST 2021, time=2021-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1303104, encodeId=02f8130310432, content=<a href='/topic/show?id=4264134043c' target=_blank style='color:#2F92EE;'>#Opdivo#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13404, encryptionId=4264134043c, topicName=Opdivo)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Fri Oct 23 06:12:45 CST 2020, time=2020-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364905, encodeId=23bb136490543, content=<a href='/topic/show?id=da511390508' target=_blank style='color:#2F92EE;'>#PD-1单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13905, encryptionId=da511390508, topicName=PD-1单抗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8fc0211, createdName=doctor-chen9582, createdTime=Fri Oct 23 06:12:45 CST 2020, time=2020-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1384225, encodeId=4556138422545, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17503, encryptionId=14bb1e503a0, topicName=TKI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b73f484, createdName=lsj628, createdTime=Fri Oct 23 06:12:45 CST 2020, time=2020-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1598075, encodeId=04df15980e570, content=<a href='/topic/show?id=6c6f1e62c5' target=_blank style='color:#2F92EE;'>#ABO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1762, encryptionId=6c6f1e62c5, topicName=ABO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b6c918580135, createdName=闆锋旦, createdTime=Fri Oct 23 06:12:45 CST 2020, time=2020-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621286, encodeId=2d4916212863e, content=<a href='/topic/show?id=5f1f139091f' target=_blank style='color:#2F92EE;'>#PD-1单抗Opdivo#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13909, encryptionId=5f1f139091f, topicName=PD-1单抗Opdivo)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bc4a20243913, createdName=ymljack, createdTime=Fri Oct 23 06:12:45 CST 2020, time=2020-10-23, status=1, ipAttribution=)]
    2021-08-09 jklm09
  4. [GetPortalCommentsPageByObjectIdResponse(id=2081218, encodeId=d9112081218db, content=<a href='/topic/show?id=7f1b25e40ce' target=_blank style='color:#2F92EE;'>#优先评审#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25740, encryptionId=7f1b25e40ce, topicName=优先评审)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Sun May 02 04:12:45 CST 2021, time=2021-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896765, encodeId=28991896e657f, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Tue Mar 02 20:12:45 CST 2021, time=2021-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852518, encodeId=92dd1852518b3, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Aug 09 04:12:45 CST 2021, time=2021-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1303104, encodeId=02f8130310432, content=<a href='/topic/show?id=4264134043c' target=_blank style='color:#2F92EE;'>#Opdivo#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13404, encryptionId=4264134043c, topicName=Opdivo)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Fri Oct 23 06:12:45 CST 2020, time=2020-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364905, encodeId=23bb136490543, content=<a href='/topic/show?id=da511390508' target=_blank style='color:#2F92EE;'>#PD-1单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13905, encryptionId=da511390508, topicName=PD-1单抗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8fc0211, createdName=doctor-chen9582, createdTime=Fri Oct 23 06:12:45 CST 2020, time=2020-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1384225, encodeId=4556138422545, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17503, encryptionId=14bb1e503a0, topicName=TKI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b73f484, createdName=lsj628, createdTime=Fri Oct 23 06:12:45 CST 2020, time=2020-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1598075, encodeId=04df15980e570, content=<a href='/topic/show?id=6c6f1e62c5' target=_blank style='color:#2F92EE;'>#ABO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1762, encryptionId=6c6f1e62c5, topicName=ABO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b6c918580135, createdName=闆锋旦, createdTime=Fri Oct 23 06:12:45 CST 2020, time=2020-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621286, encodeId=2d4916212863e, content=<a href='/topic/show?id=5f1f139091f' target=_blank style='color:#2F92EE;'>#PD-1单抗Opdivo#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13909, encryptionId=5f1f139091f, topicName=PD-1单抗Opdivo)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bc4a20243913, createdName=ymljack, createdTime=Fri Oct 23 06:12:45 CST 2020, time=2020-10-23, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2081218, encodeId=d9112081218db, content=<a href='/topic/show?id=7f1b25e40ce' target=_blank style='color:#2F92EE;'>#优先评审#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25740, encryptionId=7f1b25e40ce, topicName=优先评审)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Sun May 02 04:12:45 CST 2021, time=2021-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896765, encodeId=28991896e657f, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Tue Mar 02 20:12:45 CST 2021, time=2021-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852518, encodeId=92dd1852518b3, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Aug 09 04:12:45 CST 2021, time=2021-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1303104, encodeId=02f8130310432, content=<a href='/topic/show?id=4264134043c' target=_blank style='color:#2F92EE;'>#Opdivo#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13404, encryptionId=4264134043c, topicName=Opdivo)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Fri Oct 23 06:12:45 CST 2020, time=2020-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364905, encodeId=23bb136490543, content=<a href='/topic/show?id=da511390508' target=_blank style='color:#2F92EE;'>#PD-1单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13905, encryptionId=da511390508, topicName=PD-1单抗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8fc0211, createdName=doctor-chen9582, createdTime=Fri Oct 23 06:12:45 CST 2020, time=2020-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1384225, encodeId=4556138422545, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17503, encryptionId=14bb1e503a0, topicName=TKI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b73f484, createdName=lsj628, createdTime=Fri Oct 23 06:12:45 CST 2020, time=2020-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1598075, encodeId=04df15980e570, content=<a href='/topic/show?id=6c6f1e62c5' target=_blank style='color:#2F92EE;'>#ABO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1762, encryptionId=6c6f1e62c5, topicName=ABO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b6c918580135, createdName=闆锋旦, createdTime=Fri Oct 23 06:12:45 CST 2020, time=2020-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621286, encodeId=2d4916212863e, content=<a href='/topic/show?id=5f1f139091f' target=_blank style='color:#2F92EE;'>#PD-1单抗Opdivo#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13909, encryptionId=5f1f139091f, topicName=PD-1单抗Opdivo)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bc4a20243913, createdName=ymljack, createdTime=Fri Oct 23 06:12:45 CST 2020, time=2020-10-23, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2081218, encodeId=d9112081218db, content=<a href='/topic/show?id=7f1b25e40ce' target=_blank style='color:#2F92EE;'>#优先评审#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25740, encryptionId=7f1b25e40ce, topicName=优先评审)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Sun May 02 04:12:45 CST 2021, time=2021-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896765, encodeId=28991896e657f, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Tue Mar 02 20:12:45 CST 2021, time=2021-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852518, encodeId=92dd1852518b3, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Aug 09 04:12:45 CST 2021, time=2021-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1303104, encodeId=02f8130310432, content=<a href='/topic/show?id=4264134043c' target=_blank style='color:#2F92EE;'>#Opdivo#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13404, encryptionId=4264134043c, topicName=Opdivo)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Fri Oct 23 06:12:45 CST 2020, time=2020-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364905, encodeId=23bb136490543, content=<a href='/topic/show?id=da511390508' target=_blank style='color:#2F92EE;'>#PD-1单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13905, encryptionId=da511390508, topicName=PD-1单抗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8fc0211, createdName=doctor-chen9582, createdTime=Fri Oct 23 06:12:45 CST 2020, time=2020-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1384225, encodeId=4556138422545, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17503, encryptionId=14bb1e503a0, topicName=TKI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b73f484, createdName=lsj628, createdTime=Fri Oct 23 06:12:45 CST 2020, time=2020-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1598075, encodeId=04df15980e570, content=<a href='/topic/show?id=6c6f1e62c5' target=_blank style='color:#2F92EE;'>#ABO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1762, encryptionId=6c6f1e62c5, topicName=ABO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b6c918580135, createdName=闆锋旦, createdTime=Fri Oct 23 06:12:45 CST 2020, time=2020-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621286, encodeId=2d4916212863e, content=<a href='/topic/show?id=5f1f139091f' target=_blank style='color:#2F92EE;'>#PD-1单抗Opdivo#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13909, encryptionId=5f1f139091f, topicName=PD-1单抗Opdivo)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bc4a20243913, createdName=ymljack, createdTime=Fri Oct 23 06:12:45 CST 2020, time=2020-10-23, status=1, ipAttribution=)]
    2020-10-23 lsj628
  7. [GetPortalCommentsPageByObjectIdResponse(id=2081218, encodeId=d9112081218db, content=<a href='/topic/show?id=7f1b25e40ce' target=_blank style='color:#2F92EE;'>#优先评审#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25740, encryptionId=7f1b25e40ce, topicName=优先评审)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Sun May 02 04:12:45 CST 2021, time=2021-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896765, encodeId=28991896e657f, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Tue Mar 02 20:12:45 CST 2021, time=2021-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852518, encodeId=92dd1852518b3, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Aug 09 04:12:45 CST 2021, time=2021-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1303104, encodeId=02f8130310432, content=<a href='/topic/show?id=4264134043c' target=_blank style='color:#2F92EE;'>#Opdivo#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13404, encryptionId=4264134043c, topicName=Opdivo)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Fri Oct 23 06:12:45 CST 2020, time=2020-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364905, encodeId=23bb136490543, content=<a href='/topic/show?id=da511390508' target=_blank style='color:#2F92EE;'>#PD-1单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13905, encryptionId=da511390508, topicName=PD-1单抗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8fc0211, createdName=doctor-chen9582, createdTime=Fri Oct 23 06:12:45 CST 2020, time=2020-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1384225, encodeId=4556138422545, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17503, encryptionId=14bb1e503a0, topicName=TKI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b73f484, createdName=lsj628, createdTime=Fri Oct 23 06:12:45 CST 2020, time=2020-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1598075, encodeId=04df15980e570, content=<a href='/topic/show?id=6c6f1e62c5' target=_blank style='color:#2F92EE;'>#ABO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1762, encryptionId=6c6f1e62c5, topicName=ABO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b6c918580135, createdName=闆锋旦, createdTime=Fri Oct 23 06:12:45 CST 2020, time=2020-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621286, encodeId=2d4916212863e, content=<a href='/topic/show?id=5f1f139091f' target=_blank style='color:#2F92EE;'>#PD-1单抗Opdivo#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13909, encryptionId=5f1f139091f, topicName=PD-1单抗Opdivo)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bc4a20243913, createdName=ymljack, createdTime=Fri Oct 23 06:12:45 CST 2020, time=2020-10-23, status=1, ipAttribution=)]
    2020-10-23 闆锋旦
  8. [GetPortalCommentsPageByObjectIdResponse(id=2081218, encodeId=d9112081218db, content=<a href='/topic/show?id=7f1b25e40ce' target=_blank style='color:#2F92EE;'>#优先评审#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25740, encryptionId=7f1b25e40ce, topicName=优先评审)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Sun May 02 04:12:45 CST 2021, time=2021-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896765, encodeId=28991896e657f, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Tue Mar 02 20:12:45 CST 2021, time=2021-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852518, encodeId=92dd1852518b3, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Aug 09 04:12:45 CST 2021, time=2021-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1303104, encodeId=02f8130310432, content=<a href='/topic/show?id=4264134043c' target=_blank style='color:#2F92EE;'>#Opdivo#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13404, encryptionId=4264134043c, topicName=Opdivo)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Fri Oct 23 06:12:45 CST 2020, time=2020-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364905, encodeId=23bb136490543, content=<a href='/topic/show?id=da511390508' target=_blank style='color:#2F92EE;'>#PD-1单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13905, encryptionId=da511390508, topicName=PD-1单抗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8fc0211, createdName=doctor-chen9582, createdTime=Fri Oct 23 06:12:45 CST 2020, time=2020-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1384225, encodeId=4556138422545, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17503, encryptionId=14bb1e503a0, topicName=TKI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b73f484, createdName=lsj628, createdTime=Fri Oct 23 06:12:45 CST 2020, time=2020-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1598075, encodeId=04df15980e570, content=<a href='/topic/show?id=6c6f1e62c5' target=_blank style='color:#2F92EE;'>#ABO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1762, encryptionId=6c6f1e62c5, topicName=ABO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b6c918580135, createdName=闆锋旦, createdTime=Fri Oct 23 06:12:45 CST 2020, time=2020-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621286, encodeId=2d4916212863e, content=<a href='/topic/show?id=5f1f139091f' target=_blank style='color:#2F92EE;'>#PD-1单抗Opdivo#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13909, encryptionId=5f1f139091f, topicName=PD-1单抗Opdivo)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bc4a20243913, createdName=ymljack, createdTime=Fri Oct 23 06:12:45 CST 2020, time=2020-10-23, status=1, ipAttribution=)]

相关资讯

Brit J Cancer:mTORC1/2抑制剂sapanisertib 在肾癌、子宫内膜癌或膀胱癌扩张期晚期实体肿瘤的一期研究

Sapanisertib是一种口服的mTORC1/mTORC2的高选择性抑制剂。在近期发表在british journal of cancer期刊上的一项研究中,来自美国纪念斯隆-凯特琳癌症中心的科学

Cell Death & Disease:长非编码RNA SNHG12能够促进肿瘤进展和sunitinib抗性

肾细胞肿瘤(RCC)是泌尿系统中最常见的恶性肿瘤之一,靶向药物治疗在RCC中也很常用。长非编码RNA SNHG12(lncRNA SNHG12)已经成为大量人类癌症的一个关键分子,但是其在肾细胞肿瘤s

Nat Med:阿维鲁单抗联合阿西替尼与舒尼替尼治疗晚期肾细胞癌:JAVELIN Renal 1013期试验生物标志物分析

在近期发表在nature medicine期刊的一项研究中来自美国纪念斯隆凯特琳癌症中心的研究人员报告了阿维鲁单抗联合阿西替尼治疗先前未经治疗的肾细胞癌患者的Ⅲ期临床研究(JAVELIN Renal

盘点:肾肿瘤研究小结

肾脏的生理功能主要是排泄代谢产物及调节水、电解质和酸碱平衡,分泌多种活性物质,维持机体内环境稳定,以保证机体的正常生理功能。肾炎是由免疫介导的、炎症介质(如补体、细胞因子、活性氧等)参与的,最后导致肾

Cell Death & Disease:新研究揭示LncRNA CDKN2B-AS1/miR-141/cyclin D网络能调控肾细胞癌的肿瘤进展和转移

肾细胞癌(RCC)的分子异质性使晚期转移性疾病的治疗干预变得复杂,因此其管理仍是一个重大挑战。在近期发表在Cell Death & Disease 期刊伤的一项研究中,来自美国加州大学旧金山分

Nat Med:液体活检可准确检测早期肾癌

肾癌是泌尿外科常见的恶性肿瘤,发病率占成人恶性肿瘤的2%~3%,虽然肾癌的症状有很多,但肾癌的诊断是不容易的。最近发表在《自然医学》杂志上的一项研究表明,液体活检可准确检测早期肾癌。